Vor Biopharma Inc.
VOR
$23.83
-$1.27-5.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 120.65% | 132.55% | 81.38% | 36.43% | 6.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.69% | 206.62% | 207.52% | 211.89% | 194.39% |
| Operating Income | 59.69% | -206.62% | -207.52% | -211.89% | -194.39% |
| Income Before Tax | 137.72% | -644.61% | -495.29% | -2,078.10% | -1,309.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 137.72% | -644.61% | -495.29% | -2,078.10% | -1,309.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 137.72% | -644.61% | -495.29% | -2,078.10% | -1,309.41% |
| EBIT | 59.69% | -206.62% | -207.52% | -211.89% | -194.39% |
| EBITDA | 59.20% | -213.67% | -214.29% | -218.32% | -199.35% |
| EPS Basic | 84.26% | -871.17% | -761.56% | -1,072.25% | -685.97% |
| Normalized Basic EPS | 84.13% | -872.36% | -762.62% | -1,072.73% | -685.97% |
| EPS Diluted | 84.26% | -871.17% | -761.56% | -1,072.25% | -685.97% |
| Normalized Diluted EPS | 84.13% | -872.36% | -762.62% | -1,072.73% | -685.97% |
| Average Basic Shares Outstanding | 539.71% | 359.88% | 187.33% | 66.43% | 42.98% |
| Average Diluted Shares Outstanding | 539.71% | 359.88% | 187.33% | 66.43% | 42.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |